AstraZeneca
🇬🇧United Kingdom
- Country
- 🇬🇧United Kingdom
- Ownership
- Public
- Employees
- 89.9K
- Market Cap
- $270.3B
- Website
- http://www.astrazeneca.co.uk
- Introduction
AstraZeneca Plc is a holding company, which engages in the research, development, manufacture, and commercialization of prescription medicines. The company was founded on June 17, 1992 and is headquartered in Cambridge, the United Kingdom.
Symbicort Rapihaler Therapeutic Equivalence Study
Phase 3
Completed
- Conditions
- Bronchial Asthma
- Interventions
- First Posted Date
- 2007-09-28
- Last Posted Date
- 2012-08-15
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 742
- Registration Number
- NCT00536731
- Locations
- 🇵🇱
Research Site, Wroclaw, Poland
Percentage of Secondary Prevention Patients Treated to Their LDL-C Targets
Completed
- Conditions
- HyperlipidemiasPeripheral Vascular DiseasesDiabetes MellitusAtherosclerosisCoronary Heart DiseaseCarotid Stenosis
- First Posted Date
- 2007-09-28
- Last Posted Date
- 2014-10-30
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 951
- Registration Number
- NCT00536965
- Locations
- 🇦🇹
Research Site, Vienna, Austria
Evaluation of Safety and Efficacy of Symbicort® pMDI, With or Without Spacer, in Children (6-11 Years) With Asthma
Phase 3
Completed
- Conditions
- Asthma
- Interventions
- Drug: Budesonide/formoterol pMDI 40/2.25ug + spacerDrug: Budesonide/formoterol pMDI 40/2.25 ug
- First Posted Date
- 2007-09-28
- Last Posted Date
- 2012-04-06
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 107
- Registration Number
- NCT00536913
- Locations
- 🇷🇺
Research Site, Moscow, Russian Federation
Percentage of Secondary Prevention Patients Treated to Their LDL-C Targets
Completed
- Conditions
- Peripheral Vascular DiseasesAtherosclerosisHyperlipidemiasDiabetes MellitusCoronary Heart DiseaseCarotid Stenosis
- First Posted Date
- 2007-09-28
- Last Posted Date
- 2014-10-30
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 1096
- Registration Number
- NCT00536796
- Locations
- 🇦🇹
Research Site, Rohrbach, Upper Austria, Austria
Study to Assess Safety/Tolerability/Efficacy of Gefitinib Versus Docetaxel in Locally Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC)
Phase 4
Terminated
- Conditions
- Carcinoma, Non-Small-Cell Lung
- Interventions
- First Posted Date
- 2007-09-27
- Last Posted Date
- 2013-10-01
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 14
- Registration Number
- NCT00536107
- Locations
- 🇨🇳
Research Site, Taipei, Taiwan
What is the Predictive Value of the Reflux Impact Scale
Terminated
- Conditions
- Gastroesophageal Reflux DiseaseGERDHeartburnAcid RegurgitationRetrosternal Pain
- First Posted Date
- 2007-09-27
- Last Posted Date
- 2008-07-09
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 938
- Registration Number
- NCT00536328
Generalized Anxiety Disorder Adjunct Study
Phase 3
Completed
- Conditions
- Anxiety NeurosesAnxiety StatesAnxietyAnxiety Disorders
- Interventions
- Drug: Placebo
- First Posted Date
- 2007-09-26
- Last Posted Date
- 2011-04-14
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 409
- Registration Number
- NCT00534599
- Locations
- 🇺🇸
Research Site, Spokane, Washington, United States
Unraveling the Relation of Patient's Profile and Therapeutical Effects of Atypicals, Including Quetiapine Effect
Completed
- Conditions
- ManiaSchizophrenia
- First Posted Date
- 2007-09-24
- Last Posted Date
- 2011-12-14
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 387
- Registration Number
- NCT00534222
- Locations
- 🇳🇱
Research Site, Amsterdam, Netherlands
A Non-interventional Naturalistic Project to Investigate the Effect of the Use of SMS Text Service on Treatment Adherence in Patients Treated With Seroquel® (Quetiapine)
Completed
- Conditions
- Bipolar DisorderSchizophrenia
- First Posted Date
- 2007-09-21
- Last Posted Date
- 2010-12-09
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 128
- Registration Number
- NCT00533260
- Locations
- 🇳🇱
Research Site, Wolfheze, Netherlands
A 3-Month Non-Interventional Study of Asthmatics Treatment With Symbicort® Turbuhaler®
Completed
- Conditions
- Asthma
- First Posted Date
- 2007-09-21
- Last Posted Date
- 2009-06-09
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 310
- Registration Number
- NCT00532922
- Locations
- 🇨🇳
Research Site, Shanghai, China
© Copyright 2025. All Rights Reserved by MedPath